Alcoa Inc. (AA) fell 2.4 percent to $9.14. The biggest U.S. aluminum producer will close 12 percent of its global smelting capacity after the price of the lightweight metal slumped as global supply exceeds demand. The cuts are expected to be completed in the first half of this year.
Apollo Group Inc. (APOL) : The operator of the University of Phoenix and the biggest U.S. for-profit college reported fiscal first-quarter profit and sales that topped analysts’ estimates as more new students signed up for classes.
Bank of America Corp. (BAC) declined 1.4 percent to $6.22. An Obama administration official who asked for anonymity denied speculation that the White House is considering a trillion-dollar plan to refinance home loans. The bank surged earlier amid speculation the U.S. may introduce a new mortgage refinancing program.
Family Dollar Stores Inc. (FDO) : The discount retailer reported fiscal first-quarter revenue of $2.15 billion, missing the average analyst estimate of $2.17 billion. Comparable store sales increased 4.1 percent, compared with the average analyst estimate of 4.9 percent.
Integra LifeSciences Holdings Corp. (IART) : The maker of skin-graft materials for burn victims reported preliminary fourth-quarter revenue of $203 million at most, below the average analyst estimate of $213 million.
Ista Pharmaceuticals Inc. (ISTA) : The developer of eye treatments said in a statement that a U.S. patent allowance has been granted for its Prolensa treatment, with the patent expected to issue in the first half of this year and commercial launch of the therapy following approval planned for early 2013.
Jazz Pharmaceuticals Inc. (JAZZ) : The drugmaker said earnings in 2012 will be as much as $4.15, compared with the average analyst estimate of $3.39. The forecast reflects earnings after the company completes the acquisition of Azur Pharma.
RF Micro Devices Inc. (RFMD) fell 20 percent to $4.51. The U.S. maker of chips and radio systems for mobile phones cut its forecast for fiscal third-quarter revenue to $225 million, compared with a previous estimate of $250 million. The company was cut to “market perform” from “outperform” at Oppenheimer & Co.
ViroPharma Inc. (VPHM) : The pharmaceutical company forecast 2012 sales of as much as $660 million, above the average analyst estimate of $602 million.
Xyratex Ltd. (XRTX) : The provider of data storage and network technology reported fiscal fourth-quarter earnings of 73 cents a share, excluding some items, beating the average analyst estimate of 33 cents.